# OnCo record stage-ii-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/stage-ii-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "stage-ii-melanoma" ;
  schema:name "Stage IIB and IIC melanoma"@en ;
  schema:alternateName "High-risk stage II melanoma"@en, "Thick node-negative melanoma"@en, "Stage IIB/IIC melanoma"@en ;
  schema:description "Stage IIB and IIC melanomas are thick or ulcerated skin melanomas that have not reached the lymph nodes but still carry a real risk of coming back. A year of pembrolizumab or nivolumab after surgery lowers that risk, though most people in this group would have been cured by surgery alone, so the decision weighs a modest benefit against a year of treatment."@en ;
  schema:url <https://onco.cc/cancers/stage-ii-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Melanoma> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(22)00562-1>, <https://doi.org/10.1038/s41591-023-02583-2>, <https://en.wikipedia.org/wiki/Melanoma> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/intismeran-autogene/> ;
  onco:terms <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/terms/ulceration-melanoma/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/keynote-716/>, <https://onco.cc/trials/nct04099251/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/trials/nct05270044/> ;
  onco:people <https://onco.cc/people/jason-luke/> ;
  onco:pipeline <https://onco.cc/trials/interpath-001/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/trials/nct05270044/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:standardOfCare <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/trials/keynote-716/>, <https://onco.cc/trials/nct04099251/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/technologies/skin-cancer-screening/>, <https://onco.cc/technologies/dermoscopy-ai/> .